Status:

COMPLETED

TheraSphere HUD For Treatment of Unresectable Hepatocellular Carcinoma (HCC)

Lead Sponsor:

University of Louisville

Collaborating Sponsors:

MDS Pharma Services

Conditions:

Hepatocellular Carcinoma

Eligibility:

All Genders

18+ years

Brief Summary

The purpose of this protocol is to provide access to Therasphere treatment for patients with liver tumors.

Detailed Description

Surgical resection of the affected portion of the liver offers the best chance for disease-free survival in patients with primary liver cancer (hepatocellular carcinoma (HCC)). Unfortunately, most of ...

Eligibility Criteria

Inclusion

  • Patients over 18 years of age, of any race or sex, who have histologic proof of primary cancer to the liver, who are able to give informed consent, will be eligible.
  • Patients must have an ECOG Performance Status score of greater than or equal to 2, with a life expectancy of \> 3 months, non-pregnant with an acceptable contraception in premenopausal women.
  • The histopathology confirmation criterion may be waived in patients with a radiographically identifiable liver mass, known laboratory or clinical risk factors for cancer or elevated tumor markers such as AFP (clinical diagnosis).
  • Participation in the TheraSphere Registry.

Exclusion

  • Contraindications to angiography and selective visceral catheterization
  • Evidence of potential delivery of greater than 16.5 mCi (30 Gy absorbed dose) of radiation to the lungs
  • Evidence of any detectable Tc-99 MAA flow to the stomach or duodenum, after application of established angiographic techniques to stop such flow
  • Significant extrahepatic disease representing an imminent life-threatening outcome
  • Severe liver dysfunction or pulmonary insufficiency
  • Active uncontrolled infection
  • Pregnancy
  • Refusal to participate in the TheraSphere Registry

Key Trial Info

Start Date :

January 1 2004

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

April 1 2021

Estimated Enrollment :

183 Patients enrolled

Trial Details

Trial ID

NCT00683631

Start Date

January 1 2004

End Date

April 1 2021

Last Update

December 18 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Louisville Hospital / Norton Hospital

Louisville, Kentucky, United States, 40202